We're just weeks away from catalyst-after-catalyst.
1.Presenting interim response data from OncoSec's Phase II melanoma trial along with long-term progression-free survival data from its previous Phase I melanoma program
2.Presenting final data from OncoSec's Phase II melanoma trial and Merkel cell carcinoma trial
3.Conducting an end-of-Phase II meeting with the FDA for OncoSec's melanoma and Merkel cell carcinoma program
4.Presenting interim data from OncoSec's Phase II cutaneous T-cell lymphoma program
5.Launching a pivotal Merkel cell carcinoma program
6.Launching a Phase IIB metastatic melanoma program
While there is no guarantee that all, or indeed any, of the data involved with these catalysts will be positive, the remainder of the year will be a busy time for OncoSec, and if the company reports positive results it could attract the attention of investors in the same way that Inovio has over the past three months.